SEC
NVO

Seven Eight Capital’s Novo Nordisk NVO Stock Holding History

Seven Eight Capital’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-9,410
Closed -$1.34M – 888
2024
Q2 		$1.34M Sell
9,410
-24,886
-73% -$3.3M 0.14% 251
2024
Q1 		$4.4M Sell
34,296
-32,295
-48% -$3.84M 0.46% 52
2023
Q4 		$6.89M Buy
+66,591
New +$6.59M 0.8% 12
2023
Q3 		– Sell
-29,612
Closed -$2.4M – 698
2023
Q2 		$2.4M Buy
+29,612
New +$2.42M 0.4% 75
2023
Q1 		– Sell
-35,848
Closed -$2.43M – 559
2022
Q4 		$2.43M Buy
35,848
+5,222
+17% +$306K 0.63% 33
2022
Q3 		$1.53M Buy
30,626
+18,800
+159% +$1.01M 0.31% 92
2022
Q2 		$659K Buy
11,826
+5,272
+80% +$293K 0.27% 131
2022
Q1 		$364K Buy
+6,554
New +$336K 0.05% 377
2021
Q4 		– Sell
-6,758
Closed -$324K – 611
2021
Q3 		$324K Buy
+6,758
New +$327K 0.03% 494
2021
Q2 		– Sell
-91,800
Closed -$3.21M – 668
2021
Q1 		$3.21M Hold
91,800
– – 0.74% 25
2020
Q4 		$3.21M Buy
91,800
+40,000
+77% +$1.38M 0.73% 25
2020
Q3 		$1.8M Buy
51,800
+20,600
+66% +$687K 0.39% 47
2020
Q2 		$1.02M Buy
+31,200
New +$996K 0.75% 19
2018
Q3 		– Sell
-66,700
Closed -$1.54M – 661
2018
Q2 		$1.54M Buy
+66,700
New +$1.59M 0.11% 233
2017
Q1 		– Sell
-97,100
Closed -$1.74M – 630
2016
Q4 		$1.74M Buy
97,100
+31,740
+49% +$575K 0.35% 88
2016
Q3 		$1.36M Buy
+65,360
New +$1.62M 0.4% 83
2016
Q2 		– Sell
-262
Closed -$7K – 632
2016
Q1 		$7K Sell
262
-2,200
-89% -$58.9K ﹤0.01% 501
2015
Q4 		$71K Buy
+2,462
New +$68.1K 0.05% 402
2015
Q3 		– Sell
-3,062
Closed -$84K – 639
2015
Q2 		$84K Buy
3,062
+3,000
+4,839% +$84.3K 0.1% 284
2015
Q1 		$2K Hold
62
– – ﹤0.01% 439
2014
Q4 		$1K Buy
+62
New +$1.39K ﹤0.01% 458

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Seven Eight Capital's NVO Position: Q3 2024 in Review

Seven Eight Capital sold out of Novo Nordisk (NVO) in Q3 2024, closing a stake of 9,410 shares — an estimated $1.34M sold.

Seven Eight Capital first reported a position in NVO in Q4 2014 and held it in 21 quarters. The position peaked at $6.89M in Q4 2023. 1,785 funds tracked by Wall St. Rank hold NVO as of Q3 2024.

  • Seven Eight Capital reported no remaining Novo Nordisk position as of Q3 2024 after selling out during the quarter.
  • Seven Eight Capital sold 9,410 Novo Nordisk shares in Q3 2024, an estimated $1.34M.
  • Seven Eight Capital first reported a position in Novo Nordisk in Q4 2014 and held it in 21 quarters.
  • Seven Eight Capital's Novo Nordisk position peaked at $6.89M in Q4 2023.
  • 1,785 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2024.

Based on Seven Eight Capital's 13F filing for Q3 2024, filed 12 Nov 2024.